Globe Newswire

Epilepsy – Worldwide market and epidemiological findings and forecasts to 2030

Dublin, January 22, 2021 (GLOBE NEWSWIRE) –’s offering has been expanded to include the drug pipelines “Epilepsy – Market Insight, Epidemiology and Market Forecast – 2030”. This report provides an in-depth understanding of epilepsy, historical and forecast epidemiology, and epilepsy market trends in the US, EU5 (Germany, Spain, Italy, France and UK) and Japan. The Epilepsy Market report provides information on Current Treatment Practices, Emerging Drugs, and Market Share of Each Therapy, Current and Forecasted Market Size for 7-MM Epilepsy from 2017 to 2030. The report also covers the current Treatment Practice / Epilepsy Treatment Algorithm, Market Drivers, Market Barriers, and unmet medical needs to curate the best of options and assess the underlying market potential Geography covered United States EU5 (Germany, France, Italy, Spain and the United Kingdom) Japan Study period: 2017-2030 Diagnosis Multiple tests are used to determine if a person has some form of epilepsy and, if so, what type of seizures the person is having. These tests include: Imaging and monitoringMedical historyBlood testsDevelopmental, neurological, and behavioral tests Epidemiology – Key FindingsThis section provides an insight into the epilepsy epidemiology in the 7MM. The overall prevalence of epilepsy in the seven main markets in 2017 was 7,190,297. However, the total diagnosed population in the 7MM was 5,216,490 in 2017. The diagnosed prevalence cases of epilepsy in the US were found 2,808,599 in 2017. In the United States, the number of cases of generalized, focal, and other definite and indefinite epileptic seizures in adults in 2017 were 770,288, 1,482,440 and 169,560, respectively. In the United States, the number of cases of generalized seizures was The focal and other detected and indeterminate epileptic seizures in children were 158,387, 212,471 and 15,452, respectively in 2017. It was also found that in the United States, the number of men and women with epilepsy in 2017 were 1,477,323 and 1,331,276, respectively. In the EU5 countries, the prevalence of epilepsy was highest in Germany with 645,784 cases, followed by the United Kingdom with 641,720 cases in 2017. The lowest number of cases It was found in Spain with 403,591 cases in 2017. In Japan, the overall prevalence of epilepsy was estimated at 1,012,659 in 2017. Country-specific epidemiology The Epidemiology segment also provides the data and findings on epilepsy epidemiology in the US, EU5 (Germany), France, Italy, Spain and the United Kingdom) and Japan. Drug Chapters The Drug Chapters segment of the Epilepsy report contains the detailed analysis of those marketed by Epilepsy Medication, as well as the mid- and late-stage medications in the pipeline. It also helps understand the details of the epilepsy clinical trial, the meaningful pharmacological measures, agreements and collaborations, the approval and patent details of each drug contained, and the latest news and press releases. Market Drugs Valtoco: NeurelisEpidiolex: Greenwich BiosciencesFintepla (ZX 008): ZogenixBriviact: UCB BiopharmaXcopri (Cenobamate): SK Life ScienceNayzilam (Midazolam), Nasal Spray CIV: UCBDiacomit: TherapeuticPharmacy-TherapeutIV: UCBDiacomit: TherapeuticPharmacy-Pharmaceuticals 203: UCBDiacomit: Therapeutative-Therapeutic-Pharmadics-UCB: Zynerba Pharma Key Market Results, this section provides an insight into the Epilepsy 7 MM market. The market size of Epilepsy in the seven major markets was estimated at USD 1,847.46 million in 2017. The United States has the largest epilepsy market size compared to EU5 (United Kingdom, Germany, Italy, Spain and France). and Japan. Among the EU5 countries, the UK had the largest market size in 2017 at USD 118.23 million, while France had the smallest market size for epilepsy at USD 72.65 million in 2017. Japan Epilepsy Market accounted for $ 121.90M in 2017 Market Outlook for the United StatesThis section provides the total Epilepsy market size and market size by therapies in the United States. The overall epilepsy market size and size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section. The overall size of the Epilepsy market and market size by therapies in Japan are presented. Epilepsy Drug Intake This section focuses on the rate of intake of the potential Dr. ugs were recently launched on the epilepsy market or are expected to be launched in the 2017-2030 study period. The analysis covers drug acceptance of the epilepsy market. Patient admission through therapies; This aids in understanding the fastest absorbed drugs, the reasons for the maximum use of new drugs, and allows drugs to be compared based on market share and size, which in turn will help investigate key factors in time to market and financial and market conditions regulatory decisions. Epilepsy Development Activities The report provides insights into various therapeutic candidates in phase II and phase III. It also analyzes key players involved in the development of targeted therapeutics. Pipeline Development Activities The report provides detailed information on collaborations, acquisitions and mergers, licenses and patent details for emerging epilepsy therapies. The researchers conduct competitive and market intelligence analysis of the Epilepsy Market by using various competitive intelligence tools including SWOT Analysis, PESTLE Analysis, Porter’s Five Forces, BCG Matrix, Market Entry Strategies, etc. The inclusion of analysis is entirely dependent on data availability. Scope of the Report The report contains the descriptive overview of Epilepsy, which explains the causes, signs and symptoms, the pathogenesis and currently available therapies. Extensive insights into the epidemiology and treatment of epilepsy were given. In addition, a comprehensive review of current and emerging therapies for epilepsy is provided along with an assessment of new therapies that will impact the current treatment landscape. A detailed review of the epilepsy market; The report includes historical and forecast information on 7 million drug use. The report provides an advantage in developing business strategy by understanding trends that are shaping and driving the 7MM Epilepsy Market. Report Highlights In the years to come, the epilepsy market will change due to increasing awareness of the disease, increased diagnosis, and additional healthcare spending around the world. This would increase the size of the market to allow drug manufacturers to penetrate the market more deeply. The companies and scientists are working to assess challenges and look for opportunities that could influence research and development in epilepsy. The therapies under development focus on novel approaches to treat / improve the disease state. According to the analysis, based on the type of seizure, epilepsy can be of three types, namely generalized, focal, and other definite and indefinite seizures. These seizures are slightly different in both children and adults. The publisher also analyzed gender-specific data on epilepsy, suggesting that it is more common in men than women. Expected start of potential therapies, Libervant / Diazepam Buccal Soluble Film (Aquestive Therapeutics), UCB0942 / Padsevonil (UCB Biopharma), Soticlestat (TAK-935 / OV935) (Takeda), CX-8998 (Jazz Pharmaceuticals), Ganaxolone (Marinus Pharmaceuticals), PF-06372865 / CVL-865 (Pfizer / Cerevel Therapeutics), Cannabidiol Oral Solution (Insys Therapeutics), Staccato Alprazolam (EngageTherapeutics / UCB), GWP42003-P (GW Research), Fintepla (Zogenix), Perampenal (Eisai) and Zygel ( Zynerba) may increase market size in EU in the coming years this will be supported by an increase in the diagnosed epilepsy population. Currently, first-line therapy for epilepsy involves the use of AEDs as either monotherapy or combination therapy. Additionally, the second and third line treatment option for epileptic patients also includes the use of AEDs themselves. However, the third line treatment option also includes surgery, VNS, deep brain stimulation, etc. In addition, certain mono- or adjunct therapies are also used to treat epilepsy. Market Insights What was the Epilepsy market share (%) distribution in 2017 and what would it look like in 2030? What would the total Epilepsy market size as well as the market size by therapies be over the 7MM during the forecast period (2020-2030)? What are the key findings in relation to the market in the 7MM and which country will have the largest Epilepsy Market size during the forecast period (2020-2030)? At what CAGR is the Epilepsy Market expected to grow at the 7MM level during the 7MM? Forecast Period (2020-2030) How would the epilepsy market outlook develop during the forecast period (2020-2030) for the 7MM? What would the epilepsy market grow like through 2030 and how big will the market be in 2030? How would the market drivers, barriers and future opportunities affect the market dynamics and the subsequent analysis of the associated trends? Companies mentioned Aquestive TherapeuticsBiocodexEisai PharmaceuticalsGlaxoSmithKlineGreenwich BiosciencesJanssen PharmaceuticalsLundbeckMeda PharmaceuticalsNeurelisPfizerQuestcor Pharmaceuticals / Mallinckrodt PharmaceuticalsRocheSK Life ScienceSupernus PharmaceuticalsUCBZogenix bespoke research. CONTACT: CONTACT: Laura Wood, Senior Press Manager For EST office hours, call 1-917-300-0470. For US / CAN toll free, call 1-800-526-8630 at 353-1-416-8900